Parahoo Kader, McDonough Suzanne, McCaughan Eilis, Noyes Jane, Semple Cherith, Halstead Elizabeth J, Neuberger Molly M, Dahm Philipp
Institute of Nursing and Health Research, University of Ulster, Coleraine, Co. Londonderry, UK.
Institute of Nursing and Health Research, University of Ulster, Newtownabbey, Co. Antrim, UK.
BJU Int. 2015 Aug;116(2):174-83. doi: 10.1111/bju.12989. Epub 2015 Mar 17.
To evaluate the effectiveness of psychosocial interventions for men with prostate cancer in improving quality of life (QoL), self-efficacy and knowledge and in reducing distress, uncertainty and depression. We searched for trials using a range of electronic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and PsycINFO to October 2013, together with hand searching of journals and reference lists. Randomised controlled trials were eligible if they included psychosocial interventions that explicitly used one or a combination of the following approaches: cognitive behavioural, psycho-educational, supportive and counselling. Interventions had to be delivered or facilitated by trained or lay personnel. Our outcomes were an improvement in QoL, self-efficacy and knowledge and a reduction in distress, uncertainty and depression. Pairs of review authors independently extracted data and assessed risk of bias. We analysed data using standardised mean differences (SMDs), random-effects models and 95% confidence intervals (CIs). In all, 19 studies with a total of 3 204 men, with a diagnosis of prostate cancer, comparing psychosocial interventions vs usual care were included in this review. Men in the psychosocial intervention group had a small, statistically significant improvement in the physical component of general health-related QoL (GHQoL) at end of intervention (SMD 0.12, 95% CI 0.01-0.22) based on low quality evidence. There was no clear evidence of benefit associated with psychosocial interventions for the mental component of GHQoL at end of intervention (SMD -0.04, 95% CI -0.15 to 0.06) based on moderate quality evidence. At end of intervention, cancer-related QoL showed a small improvement after psychosocial interventions (SMD 0.21, 95% CI 0.04-0.39). For prostate cancer-specific and symptom-related QoL, the differences between intervention and control groups were not significant. There was no clear evidence that psychosocial interventions were beneficial in improving self-efficacy at end of intervention (SMD 0.16, 95% CI -0.05 to 0.38) based on very low quality evidence. Men in the psychosocial intervention group had a moderate increase in prostate cancer knowledge at end of intervention (SMD 0.51, 95% CI 0.32-0.71) based on very low quality evidence. A small increase in knowledge with psychosocial interventions was noted at 3 months after intervention (SMD 0.31, 95% CI 0.04-0.58). The results for uncertainty (SMD -0.05, 95% CI -0.35 to 0.26) and distress (SMD 0.02, 95% CI -0.11 to 0.15) at end of intervention were compatible with both benefit and harm based on very low quality evidence. Finally, there was no clear evidence of benefit associated with psychosocial interventions for depression at end of intervention (SMD -0.18, 95% CI -0.51 to 0.15) based on very low quality evidence. The overall risk of bias in the included studies was unclear or high, primarily as the result of performance bias. No data about stage of disease or treatment with androgen-deprivation therapy were extractable for subgroup analysis. Only one study addressed adverse effects. Overall, this review shows that psychosocial interventions may have small, short-term beneficial effects on certain domains of wellbeing, as measured by the physical component of GHQoL and cancer-related QoL when compared with usual care. Prostate cancer knowledge was also increased. However, this review failed to show a statistically significant effect on other domains such as symptom-related QoL, self-efficacy, uncertainty, distress or depression. Moreover, when beneficial effects were seen, it remained uncertain whether the magnitude of effect was large enough to be considered clinically important. The quality of evidence for most outcomes was rated as very low according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, reflecting study limitations, loss to follow-up, study heterogeneity and small sample sizes. We were unable to perform meaningful subgroup analyses based on disease stage or treatment method. Although some findings of this review are encouraging, they do not provide sufficiently strong evidence to permit meaningful conclusions about the effects of these interventions in men with prostate cancer. Additional well executed and transparently reported research studies are necessary to establish the role of psychosocial interventions in men with prostate cancer.
评估心理社会干预措施对前列腺癌男性患者在改善生活质量(QoL)、自我效能感和知识水平以及减轻痛苦、不确定性和抑郁方面的有效性。我们检索了一系列电子数据库,包括截至2013年10月的Cochrane对照试验中心注册库(CENTRAL)、MEDLINE、EMBASE和PsycINFO,同时手动检索了相关期刊和参考文献列表。如果随机对照试验包括明确使用以下一种或多种方法的心理社会干预措施:认知行为疗法、心理教育、支持性疗法和咨询,则该试验符合纳入标准。干预措施必须由经过培训的人员或非专业人员提供或协助实施。我们的研究结果包括生活质量、自我效能感和知识水平的改善,以及痛苦、不确定性和抑郁的减轻。由两位综述作者独立提取数据并评估偏倚风险。我们使用标准化均数差值(SMD)、随机效应模型和95%置信区间(CI)分析数据。本综述共纳入了19项研究,总计3204名被诊断为前列腺癌的男性,这些研究比较了心理社会干预措施与常规护理。基于低质量证据,心理社会干预组的男性在干预结束时,与总体健康相关生活质量(GHQoL)的身体方面有小幅的、具有统计学意义的改善(SMD 0.12,95% CI 0.01 - 0.22)。基于中等质量证据,在干预结束时,没有明确证据表明心理社会干预措施对GHQoL的心理方面有好处(SMD -0.04,95% CI -0.15至0.06)。在干预结束时,心理社会干预后癌症相关生活质量有小幅改善(SMD 0.21,95% CI 0.04 - 0.39)。对于前列腺癌特异性和症状相关生活质量,干预组和对照组之间的差异不显著。基于极低质量证据,没有明确证据表明心理社会干预措施在干预结束时对提高自我效能感有益(SMD 0.16,95% CI -0.05至0.38)。基于极低质量证据,心理社会干预组的男性在干预结束时前列腺癌知识有适度增加(SMD 0.51,95% CI 0.32 - 0.71)。在干预后3个月时,心理社会干预使知识有小幅增加(SMD 0.31,95% CI 0.
04 - 0.58)。基于极低质量证据,干预结束时不确定性(SMD -0.05,95% CI -0.35至0.26)和痛苦(SMD 0.02,95% CI -0.11至0.15)的结果与有益和有害两种情况均相符。最后,基于极低质量证据,没有明确证据表明心理社会干预措施在干预结束时对抑郁有好处(SMD -0.18,95% CI -0.51至0.15)。纳入研究中的总体偏倚风险不明确或较高,主要是由于实施偏倚。无法提取关于疾病分期或雄激素剥夺治疗的数据用于亚组分析。只有一项研究涉及了不良反应。总体而言,本综述表明,与常规护理相比,如果以GHQoL的身体方面和癌症相关生活质量来衡量,心理社会干预措施可能对某些幸福领域有小的、短期有益影响。前列腺癌知识也有所增加。然而,本综述未能显示对其他领域如症状相关生活质量、自我效能感、不确定性、痛苦或抑郁有统计学显著影响。此外,当观察到有益效果时,效果的大小是否足以被认为具有临床重要性仍不确定。根据推荐分级的评估、制定和评价(GRADE)系统,大多数结果的证据质量被评为极低,这反映了研究的局限性、失访、研究异质性和小样本量。我们无法基于疾病分期或治疗方法进行有意义的亚组分析。尽管本综述的一些发现令人鼓舞,但它们没有提供足够有力的证据来就这些干预措施对前列腺癌男性患者的影响得出有意义的结论。需要更多执行良好且报告透明的研究来确定心理社会干预措施在前列腺癌男性患者中的作用。